Nippon India Pharma Fund
Sectoral-PharmaVery HighOPEN-ENDED
- NAV as on 9 Nov 2026
- ₹588.15+2.45%1 day
- Return since launch
- 19.8%
- 52-week range
- ₹481.82 — ₹581.04
- AUM
- ₹9,166 Cr
Nippon India Pharma Fund is a Sectoral-Pharma equity fund from Nippon India Mutual Fund with ₹9,166 Cr under management, launched in 2004. Over three years it has returned 12.8% a year, against 21.2% for its category. The expense ratio is 1.83% and the SEBI riskometer reading is Very High.
Performance
Nippon India Pharma Fund NAV and returns
Growth of the fund against its category average over the period you pick.
Over 1Y this fund returned +15.1% against +19.9% for its category.
Performance
Returns
How the fund has done against its category and its benchmark.
| Period | Fund | vs category | Category | Benchmark |
|---|---|---|---|---|
| 1Y | 21.3% | +0.5 pts | 20.8% | 29.1% |
| 2Y | 13.5% | −5.5 pts | 19.1% | 17.6% |
| 3Y | 12.8% | −8.4 pts | 21.2% | 16.0% |
| 5Y | 17.1% | +1.7 pts | 15.4% | 18.5% |
| 7Y | 17.6% | −1.2 pts | 18.9% | 18.0% |
| 10Y | 18.0% | +3.5 pts | 14.4% | 17.2% |
| Period | Fund | vs category | Category | Benchmark |
|---|---|---|---|---|
| 1M | 8.2% | −0.2 pts | 8.4% | 8.5% |
| 3M | 2.9% | −0.8 pts | 3.7% | 3.7% |
| 6M | 9.2% | −4.8 pts | 14.0% | 13.6% |
| 1Y | 14.8% | −6.0 pts | 20.8% | 19.4% |
| 2Y | 7.5% | −3.4 pts | 10.8% | 9.5% |
| 3Y | 17.6% | −3.6 pts | 21.2% | 20.0% |
| 5Y | 14.3% | −1.2 pts | 15.4% | 14.6% |
| 7Y | 21.9% | −0.5 pts | 22.4% | 21.2% |
| 10Y | 15.1% | +0.7 pts | 14.4% | 13.2% |
Since launch (10 May 2004): 19.8%
Calendar-year returns
Category average66.4%
23.9%
-9.9%
39.2%
33.7%
-3.3%
Show as a table
| Period | Fund | vs category | Category |
|---|---|---|---|
| 2025 | -3.3% | −1.3 pts | -2.0% |
| 2024 | 33.7% | −7.2 pts | 40.9% |
| 2023 | 39.2% | +2.9 pts | 36.2% |
| 2022 | -9.9% | −1.6 pts | -8.3% |
| 2021 | 23.9% | +2.2 pts | 21.7% |
| 2020 | 66.4% | −2.4 pts | 68.8% |
Returns over one year are annualised. Shorter periods are absolute.
Costs & terms
Costs and terms
What the fund charges each year, and the rules around putting money in and taking it out.
Costs
1.83%
Expense ratio as on 31 Oct 2026
Charged yearly and already deducted from the NAV.
- Base expense
- 1.51%
- Brokerage
- 0.02%
- Transaction charges
- 0.00%
- Statutory levies
- 0.30%
- Exit load
- Exit load of 1% if redeemed within 1 month.
- Lock-in
- None
Terms
- Min SIP
- ₹3,000
- Min lumpsum
- ₹5,000
- Plan
- GROWTH
- Fund type
- OPEN-ENDED
- Benchmark
- BSE Healthcare TRI
- Short-term capital gains
- Returns taxed at 20% if you redeem before 1 year
- Long-term capital gains
- After 1 year, returns above ₹1.25 lakh in a financial year are taxed at 12.5%
Risk
Risk
What the riskometer means for this fund, and how its ratios sit against the category.
Very High
Your principal is treated as being at very high risk — typically small cap, sectoral and thematic equity schemes.
| Ratio | Fund | Category avg | Read as |
|---|---|---|---|
| Alpha | -3.03 | 1.49 | Return earned above what the benchmark alone would have given. Higher is better. |
| Beta | 0.89 | 0.94 | How hard the fund moves when the market moves. Under 1 is steadier than the market. |
| Sharpe | 0.80 | 1.10 | Return earned for each unit of total risk taken. Higher is better. |
| Sortino | 1.21 | 1.81 | Return earned for each unit of downside risk. Higher is better. |
| Std. deviation | 14.85 | 15.62 | How widely monthly returns have varied around their own average. Lower is steadier. |
| Average of 5 category peers | |||
Portfolio
Nippon India Pharma Fund portfolio
Portfolio as of 30 Sep 2026
Asset allocation
- Equity97.3%
- Debt0.0%
- Other2.7%
Market cap split
- Large30.5%
- Mid40.1%
- Small29.4%
- P/E
- 38.49
- P/B
- 5.29
Top holdings
| Holding | Sector | Weight | Value | 3M chg | 6M chg | 1Y chg |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Healthcare | 11.71% | ₹1,073 Cr | +12.78% | +13.92% | +12.29% |
| Divi's Laboratories Ltd. | Healthcare | 7.10% | ₹651 Cr | +5.46% | +6.41% | +7.01% |
| Lupin Ltd. | Healthcare | 6.17% | ₹565 Cr | +7.45% | +8.45% | +7.26% |
| Cipla Ltd. | Healthcare | 6.01% | ₹551 Cr | +6.15% | +5.42% | +6.48% |
| Dr. Reddy's Laboratories Ltd. | Healthcare | 5.45% | ₹499 Cr | +6.68% | +5.96% | +5.91% |
| Apollo Hospitals Enterprise Ltd. | Healthcare | 4.89% | ₹448 Cr | +5.27% | +5.15% | +5.92% |
| Mankind Pharma Ltd. | Healthcare | 4.38% | ₹401 Cr | +4.03% | +2.87% | +2.27% |
| Sai Life Sciences Ltd. | Healthcare | 3.92% | ₹359 Cr | +3.49% | +3.15% | +2.71% |
| Ajanta Pharma Ltd. | Healthcare | 3.61% | ₹331 Cr | +3.46% | +3.36% | +2.85% |
| Glaxosmithkline Pharmaceuticals Ltd. | Healthcare | 3.11% | ₹285 Cr | +2.47% | +2.64% | +2.99% |
| Ipca Laboratories Ltd. | Healthcare | 2.87% | ₹263 Cr | +2.57% | +2.77% | +1.35% |
| Max Healthcare Institute Ltd. | Healthcare | 2.70% | ₹247 Cr | +3.32% | +3.24% | — |
| Others | Others | 2.69% | ₹248 Cr | +0.03% | +0.03% | +0.01% |
| Vijaya Diagnostic Centre Ltd. | Healthcare | 2.62% | ₹240 Cr | +2.80% | +3.15% | +3.56% |
| Gland Pharma Ltd. | Healthcare | 2.53% | ₹232 Cr | +2.21% | +1.72% | +3.24% |
| Medplus Health Services Ltd. | Healthcare | 2.53% | ₹232 Cr | +3.18% | +3.86% | +3.39% |
| Abbott India Ltd. | Healthcare | 2.32% | ₹213 Cr | +2.09% | +2.43% | +2.48% |
| Piramal Pharma Ltd. | Healthcare | 2.24% | ₹205 Cr | +1.02% | — | — |
| Thyrocare Technologies Ltd. | Healthcare | 2.24% | ₹205 Cr | +2.65% | +1.94% | +2.25% |
| Dr. Lal Pathlabs Ltd. | Healthcare | 2.17% | ₹199 Cr | +1.85% | +2.02% | +2.34% |
| Alkem Laboratories Ltd. | Healthcare | 1.82% | ₹167 Cr | +1.99% | +2.17% | +2.16% |
| Aurobindo Pharma Ltd. | Healthcare | 1.65% | ₹151 Cr | +1.75% | +2.81% | +2.27% |
| Narayana Hrudayalaya Ltd. | Healthcare | 1.61% | ₹148 Cr | +1.80% | +1.67% | +2.20% |
| Suraksha Diagnostic Ltd. | Healthcare | 1.51% | ₹138 Cr | +1.18% | +1.12% | +1.43% |
| Syngene International Ltd. | Healthcare | 1.40% | ₹128 Cr | +1.70% | +0.93% | +0.98% |
| Emcure Pharmaceuticals Ltd. | Healthcare | 1.36% | ₹125 Cr | +1.52% | +1.51% | +0.74% |
| Pfizer Ltd. | Healthcare | 1.35% | ₹123 Cr | +1.56% | +1.90% | +1.98% |
| Akums Drugs And Pharmaceuticals Ltd. | Healthcare | 1.21% | ₹111 Cr | +1.03% | +0.89% | +0.82% |
| Anthem Biosciences Ltd. | Healthcare | 1.19% | ₹109 Cr | +0.90% | +0.88% | +0.99% |
| Fortis Healthcare Ltd. | Healthcare | 1.13% | ₹104 Cr | +1.42% | +1.11% | +1.32% |
| Biocon Ltd. | Healthcare | 1.01% | ₹92.73 Cr | +0.68% | +0.67% | +1.98% |
| Sanofi India Ltd. | Healthcare | 1.00% | ₹91.79 Cr | +0.87% | +0.94% | +1.32% |
| Sanofi Consumer Healthcare India Ltd. | Healthcare | 0.89% | ₹81.25 Cr | +1.09% | +1.16% | +1.24% |
| Molbio Diagnostics Ltd. | Healthcare | 0.54% | ₹49.78 Cr | — | — | — |
| Indoco Remedies Ltd. | Healthcare | 0.48% | ₹43.96 Cr | +0.49% | +0.38% | +0.66% |
| Astrazeneca Pharma India Ltd. | Healthcare | 0.42% | ₹38.70 Cr | +0.57% | +0.62% | +0.70% |
| Concord Biotech Ltd. | Healthcare | 0.17% | ₹15.35 Cr | +0.16% | +0.14% | +0.23% |
Sectors
Instruments
Recent changes
| Holding | From | To | Weight |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 12.37% | 11.71% | -0.66% |
| Dr. Reddy's Laboratories Ltd. | 4.93% | 5.45% | +0.52% |
| Mankind Pharma Ltd. | 4.09% | 4.38% | +0.29% |
| Apollo Hospitals Enterprise Ltd. | 5.15% | 4.89% | -0.26% |
| Lupin Ltd. | 6.43% | 6.17% | -0.26% |
| Pfizer Ltd. | 1.57% | 1.35% | -0.22% |
| Max Healthcare Institute Ltd. | 2.92% | 2.70% | -0.22% |
| Thyrocare Technologies Ltd. | 2.45% | 2.24% | -0.21% |
| Glaxosmithkline Pharmaceuticals Ltd. | 3.31% | 3.11% | -0.20% |
| Abbott India Ltd. | 2.13% | 2.32% | +0.19% |
| Fortis Healthcare Ltd. | 1.29% | 1.13% | -0.16% |
| Ajanta Pharma Ltd. | 3.47% | 3.61% | +0.14% |
| Dr. Lal Pathlabs Ltd. | 2.04% | 2.17% | +0.13% |
| Suraksha Diagnostic Ltd. | 1.39% | 1.51% | +0.12% |
| Emcure Pharmaceuticals Ltd. | 1.25% | 1.36% | +0.11% |
| Molbio Diagnostics Ltd. | 0.44% | 0.54% | +0.10% |
| Akums Drugs And Pharmaceuticals Ltd. | 1.11% | 1.21% | +0.10% |
| Divi's Laboratories Ltd. | 7.00% | 7.10% | +0.10% |
| Gland Pharma Ltd. | 2.44% | 2.53% | +0.09% |
| Biocon Ltd. | 1.09% | 1.01% | -0.08% |
| Cipla Ltd. | 6.09% | 6.01% | -0.08% |
| Syngene International Ltd. | 1.48% | 1.40% | -0.08% |
| Vijaya Diagnostic Centre Ltd. | 2.68% | 2.62% | -0.06% |
| Narayana Hrudayalaya Ltd. | 1.66% | 1.61% | -0.05% |
| Astrazeneca Pharma India Ltd. | 0.46% | 0.42% | -0.04% |
| Sanofi Consumer Healthcare India Ltd. | 0.93% | 0.89% | -0.04% |
| Ipca Laboratories Ltd. | 2.84% | 2.87% | +0.03% |
| Aurobindo Pharma Ltd. | 1.63% | 1.65% | +0.02% |
| Medplus Health Services Ltd. | 2.51% | 2.53% | +0.02% |
| Sai Life Sciences Ltd. | 3.94% | 3.92% | -0.02% |
| Anthem Biosciences Ltd. | 1.20% | 1.19% | -0.01% |
| Indoco Remedies Ltd. | 0.47% | 0.48% | +0.01% |
| Sanofi India Ltd. | 0.99% | 1.00% | +0.01% |
| Others | 0.01% | 0.02% | +0.01% |
| Piramal Pharma Ltd. | 2.25% | 2.24% | -0.01% |
| Alkem Laboratories Ltd. | 1.82% | 1.82% | 0.00% |
| Concord Biotech Ltd. | 0.17% | 0.17% | 0.00% |
Compare
Similar funds
The rest of the category, so this fund’s numbers have something to sit against.
| Fund | AUM | Expense | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| Category average | ₹2,934 Cr | 1.89% | 36.5% | 20.8% | 21.6% |
 SBI Healthcare Opportunities Fund | ₹6,067 Cr | 1.98% | 35.0% | 19.9% | 22.6% |
 HDFC Pharma And Healthcare Fund | ₹3,501 Cr | 2.11% | 39.6% | 25.8% | — |
 Mirae Asset Healthcare Fund | ₹3,494 Cr | 2.01% | 37.3% | 20.2% | 21.1% |
 UTI Healthcare Fund | ₹1,430 Cr | 2.21% | 30.6% | 18.4% | 21.1% |
 ICICI Prudential Nifty Pharma Index Fund | ₹177 Cr | 1.13% | 39.9% | 19.9% | — |
About
About this fund
The scheme’s own words, its benchmark and the people running it.
Investment objective
The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies.
Fund managers
- Amber SinghaniaMMS Finance (Mumbai University)Prior to joining the Nippon India AMC, he was associated with Asian Markets Securities Pvt. Ltd.
- Sailesh Raj BhanMr. Bhan is an MBA (Finance) and CFA.Prior to joining Nippon India Mutual Fund, he has worked with Emkay Share & Stock Broker Pvt. Ltd, Shah & Sequeira Invst. Pvt. Ltd, ICFAI- Securities Research Center Analyst - Equity Research.
Tools
Return calculator
What ₹10,000 a month in this fund would have grown to over each period, based on its past returns.
₹
| Over the past | Total investment | Would’ve become | Growth | Returns |
|---|---|---|---|---|
| 6 months9.21% absolute | ₹60,000 | ₹65,526 | 9.21% | |
| 1 year14.78% annualised | ₹1,20,000 | ₹1,30,055 | 8.38% | |
| 3 years17.65% annualised | ₹3,60,000 | ₹4,77,089 | 32.52% | |
| 5 years14.25% annualised | ₹6,00,000 | ₹8,78,130 | 46.36% |
Returns for 1 year and longer are annualised (CAGR); 6-month figures are absolute. Past returns are not a forecast.
How this is calculated
Each monthly instalment grows at the fund’s annualised return ÷ 12 per month until the end of the period, the same formula as our SIP calculator.
The amount compounds once a year at the fund’s CAGR for that period, the same formula as our lumpsum calculator.
Questions
Frequently asked questions
The things people ask about this scheme.
What is the NAV of Nippon India Pharma Fund?
The NAV of Nippon India Pharma Fund is ₹588.15 as on 9 Nov 2026.
What is the expense ratio of Nippon India Pharma Fund?
The expense ratio of Nippon India Pharma Fund is 1.83% per year.
What is the minimum SIP amount for Nippon India Pharma Fund?
You can start a SIP in Nippon India Pharma Fund with ₹3,000 a month.
What returns has Nippon India Pharma Fund given?
Nippon India Pharma Fund has returned 21.3% over 1 year, 12.8% over 3 years and 17.1% over 5 years (annualised).
Is there a lock-in or exit load on Nippon India Pharma Fund?
Lock-in: None. Exit load: Exit load of 1% if redeemed within 1 month..
How risky is Nippon India Pharma Fund?
Nippon India Pharma Fund is rated Very High on the SEBI riskometer and belongs to the Sectoral-Pharma category.
Which fund house manages Nippon India Pharma Fund?
Nippon India Pharma Fund is managed by Nippon India Mutual Fund, which runs 75 schemes with ₹8,03,520 Cr under management.